| Identification | Back Directory | [Name]
PF 4957325 | [CAS]
1305115-80-3 | [Synonyms]
PF 4957325
PF-04957325
PF 04957325
PF04957325; PF4957325
3-[[(2R)-4-(1,3-thiazol-2-ylmethyl)morpholin-2-yl]methyl]-5-(trifluoromethyl)triazolo[4,5-d]pyrimidin-7-amine
3H-1,2,3-Triazolo[4,5-d]pyrimidin-7-amine, 3-[[(2R)-4-(2-thiazolylmethyl)-2-morpholinyl]methyl]-5-(trifluoromethyl)-
3-{[(2R)-4-(1,3-thiazol-2-ylmethyl)morpholin-2-yl]methyl}-5-(trifluoromethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine | [Molecular Formula]
C14H15F3N8OS | [MOL File]
1305115-80-3.mol | [Molecular Weight]
400.38 |
| Chemical Properties | Back Directory | [density ]
1.81±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 9.9 mg/mL (24.73 mM) | [form ]
Solid | [pka]
4.51±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PF-04957325 is a highly potent and selective PDE8 inhibitor, with IC50s of 0.7 nM and 0.3 nM for PDE8A and PDE8B, respectively. | [References]
[1] Vang AG, et al. Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation. Front Pharmacol. 2016 Aug 23;7:259. DOI:10.3389/fphar.2016.00259
[2] Dong H, et al. Inhibition of breast cancer cell migration by activation of cAMP signaling. Breast Cancer Res Treat. 2015 Jul;152(1):17-28. DOI:10.1007/s10549-015-3445-9
[3] Tsai LC, et al. Regulation of adrenal steroidogenesis by the high-affinity phosphodiesterase 8 family. Horm Metab Res. 2012 Sep;44(10):790-4. DOI:10.1055/s-0032-1321861
[4] Shimizu-Albergine M, et al. cAMP-specific phosphodiesterases 8A and 8B, essential regulators of Leydig cell steroidogenesis. Mol Pharmacol. 2012 Apr;81(4):556-66. DOI:10.1124/mol.111.076125 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|